May 13, 2025 01:00PM
May 13, 2025 01:00PM
May 13, 2025 01:00PM
May 13, 2025 01:00PM
May 6, 2025 04:30PM
May 1, 2025 01:31PM
May 1, 2025 01:30PM ACELYRIN Reiterates Benefits of Value-Maximizing Combination with Alumis
Apr 21, 2025 06:36AM
Apr 21, 2025 06:30AM
Apr 4, 2025 04:36PM
Apr 4, 2025 04:34PM
Mar 13, 2025 07:01AM
Mar 13, 2025 07:00AM
Mar 4, 2025 09:05AM Alumis (ALMS) and ACELYRIN (SLRN) Reaffirm Strategic and Financial Rationale of Proposed Merger
Mar 4, 2025 09:01AM
Mar 4, 2025 09:01AM
Mar 4, 2025 09:00AM
Feb 21, 2025 07:21AM
Feb 20, 2025 09:00PM
Feb 6, 2025 04:16PM
Feb 6, 2025 04:15PM Alumis and ACELYRIN to Merge Creating a Late-Stage Clinical Biopharma Company Dedicated to Innovating, Developing and Commercializing Transformative Therapies for Immune-mediated Diseases
Jan 6, 2025 04:00PM
Jan 6, 2025 04:00PM
Jan 2, 2025 08:00PM
Dec 10, 2024 04:31PM
Dec 10, 2024 04:30PM
Nov 13, 2024 04:00PM
Jun 5, 2024 07:00AM Acelyrin (SLRN) Reports Positive 16-week Data From its Global Phase 2b/3 Trial of Izokibep
Jun 5, 2024 07:00AM
May 29, 2024 07:00AM
May 9, 2024 08:01AM
May 9, 2024 08:01AM
May 9, 2024 08:00AM
Mar 28, 2024 04:05PM
Mar 27, 2024 04:01PM Avalo Therapuetics (AVTX) Acquires Anti-IL-1β mAb and Announces Private Placement Financing of up to $185 Million
Mar 27, 2024 04:01PM
Jan 2, 2024 09:00PM
Dec 28, 2023 09:00PM
Nov 27, 2023 04:30PM
Nov 7, 2023 04:05PM
Sep 12, 2023 07:50AM
Aug 14, 2023 04:05PM ACELYRIN, INC. Reports Second Quarter 2023 Financial Results and Recent Highlights
Jun 15, 2023 04:05PM

1,122,779 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All